Compound in Magic Mushrooms Could Treat Depression

D-briefBy Carl EngelkingMay 9, 2014 7:55 PM


Sign up for our email newsletter for the latest science news

Psilocybin, the naturally occurring psychedelic compound in magic mushrooms, is a Schedule I illegal drug in the United States, which means it serves no legitimate medical purpose. But researchers in Switzerland believe psilocybin could help reduce the symptoms of anxiety and depression. In a new study, researchers from the Psychiatric University Hospital of Zurich have shown that even small amounts of psilocybin can weaken the way our brains process negative emotions and provide a positive mood lift. Psilocybin, researchers conclude, could aid in normalizing depressive patients’ exaggerated processing of negative stimuli.

Psilocybin on the Brain

To test how psilocybin affects the brain, researchers recruited 25 healthy individuals and gave one group a small dose of the hallucinogen, and another a placebo. They monitored participants' brain activity in real time using fMRI whileparticipants were shown photos. Some photos depicted negative scenes, such as aggressive animals, weapons, and injured people; others displayed neutral everyday scenes, such as a couple riding bikes. The researchers also used questionnaires to assess participants’ mood before and after taking the drug. The researchers found that a part of the brain called the amygdala, which processes negative emotions like anxiety and fear, showed very different activity in the two groups. Subjects who had taken psilocybin showed less activity in their amygdala in response to both negative and neutral stimuli, and they reported a boost in mood. And the two were related: the greater the amydala dampening in response to negative images, the bigger the mood boost. Researchers recently published the results in the journal Biological Psychiatry.

Testing Depressive Patients

As part of the central circuitry of emotion, the amygdala is thought to be a key player in the development of depression and anxiety. Rainer Krahenmann, the study’s author, said the next step is to investigate whether psilocybin normalizes amygdala function in patients who are diagnosed with depression. He said further research of the compound could lead to novel approaches for treating the mental disorder.

Photo credit: Shots Studio/Shutterstock

1 free article left
Want More? Get unlimited access for as low as $1.99/month

Already a subscriber?

Register or Log In

1 free articleSubscribe
Discover Magazine Logo
Want more?

Keep reading for as low as $1.99!


Already a subscriber?

Register or Log In

More From Discover
Recommendations From Our Store
Shop Now
Stay Curious
Our List

Sign up for our weekly science updates.

To The Magazine

Save up to 70% off the cover price when you subscribe to Discover magazine.

Copyright © 2023 Kalmbach Media Co.